TransCode Therapeutics (RNAZ) Stock: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$1.70
-0.10 (-5.56%)
âŧ
5d:
-8.6%
30d:
-1.16%
90d:
-79.83%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 13, 2026
26d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RNAZ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RNAZ is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $1.70, which is considered fair relative to its 30-day fair value range of $1.63 to $1.78.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.57, while resistance sits at $1.95. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: RNAZ scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+488.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.57, while resistance sits at $1.95. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: RNAZ scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+488.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.63 -
$1.78
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 488.2% below Wall St target ($10.00)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.63 -
$1.78
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.57
Resistance Level
$1.95
Current Trend
Strong Downtrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.31
Wall Street Target
$10.00
(+488.2%)
Share & Embed Analysis
Last updated: October 17, 2026 11:17 AM ET
Data refreshes hourly during market hours. Next update: 12:17 PM
Data refreshes hourly during market hours. Next update: 12:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
27 analysts |
$92 | 70 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 74 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 51 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 71 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$129 | 71 BUY |
